Cargando…
Traditional Chinese patent medicines for cancer treatment in China: a nationwide medical insurance data analysis
Based on the nationwide survey into inpatients' utilization of the health service covered by China's urban basic medical insurance from 2008 to 2010, we analyzed the use rate, cancer profile and combined use of anticancer Chinese patent medicines (CPMs) on 51,382 insured cancer patients by...
Autores principales: | Wu, Min, Lu, Peng, Shi, Luwen, Li, Shao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741999/ https://www.ncbi.nlm.nih.gov/pubmed/26513017 |
Ejemplares similares
-
Off-Label Use of Antineoplastic Drugs to Treat Malignancies: Evidence From China Based on a Nationwide Medical Insurance Data Analysis
por: Wei, Guoxu, et al.
Publicado: (2021) -
Assesment of Adulterated Traditional Chinese Medicines in China: 2003-2017
por: Xu, Mingzhe, et al.
Publicado: (2019) -
Traditional Chinese Patent Medicine for Primary Hypertension: A Bayesian Network Meta-Analysis
por: Chen, Zhe, et al.
Publicado: (2020) -
Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines
por: Wu, Ying, et al.
Publicado: (2021) -
Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19
por: Ni, Li, et al.
Publicado: (2020)